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List of abbreviations 
2hPG: Plasma glucose value at 120 min of the OGTT.  
βC-GS: beta-cell glucose sensitivity as measured by the slope of the glucose-insulin secretion curve 
obtained through plasma C-peptide and glucose OGTT data modeling.  
δOGTT: post-load glucose homeostasis described as the area of the plasma glucose curve above the 
fasting level during the OGTT, divided by 120 minutes (mmol·L
-1
).
AIR: Acute Insulin Response as measured through the IVGTT. 
AIR/G: ratio of the area under the curve of C-peptide to the maximal plasma glucose concentration 
gradient achieved with the bolus over 8 minutes. 
Clamp M: Glucose disposal at steady state during an euglycemic hyperinsulinemic clamp. 
DBP: Diastolic Blood Pressure . 
EGP: endogenous glucose production. 
FPG: fasting plasma glucose. 
FPI: fasting plasma insulin. 
GCRf/If: ratio of glucose clearance and insulin at fasting, as measure of whole-body fasting insulin 
sensitivity. 
GCRc/Ic: ratio of glucose clearance and insulin during clamp, as measure of peripheral insulin 
sensitivity. 
IFG: Impaired Fasting Glucose. 
IGT: Impaired Glucose Tolerance. 
ISR: Insulin Secretion Rate. 
ISR@5: Insulin Secretion Rate at 5 mM glucose (ISR@5), representing the value of insulin 
secretion that in each individual would occur at 5 mM glucose reflecting the basal (non-stimulated) 
beta-cell function.  
ISR fast: Insulin Secretion Rate at fasting glucose concentrations. 
ISR OGTT: Insulin Secretion Rate at OGTT glucose concentrations. 
NGT: Normal Glucose Tolerance. 
PFR: Potentiation factor ratio, an index of the enhancement of insulin secretion due to a previous 
exposure to hyperglycemia obtained through OGTT plasma C-peptide and glucose data modeling. 
RISC: Relationship between Insulin Sensitivity and Cardiovascular risk. 
RS: Rate sensitivity an index of the dynamic response of the beta-cell to the early rise in plasma 
glucose as derived from OGTT plasma C-peptide and glucose data modeling. 



































































Background/aims – Uncertainty still exists on the earliest beta-cell defects at the bases of the type 
2 diabetes. We assume that this depends on the inaccurate distinction between fasting and post-load 
glucose homeostasis and aim at providing a description of major beta-cell functions across the full 
physiologic spectrum of each condition. 
Methods – In 1,320 non-diabetic individuals we performed an OGTT with insulin secretion 
modeling and a euglycemic insulin clamp, coupled in subgroups to glucose tracers and IVGTT; 
1,038 subjects underwent another OGTT after 3.5 years. Post-load glucose homeostasis was defined 
as mean plasma glucose above fasting levels (δOGTT). The analysis was performed by two-way 
ANCOVA. 
Results - Fasting plasma glucose (FPG) and δOGTT were weakly related variables (stβ=0.12) as 
were their changes over time (r=-0.08). Disruption of FPG control was associated with an isolated 
and progressive decline (approaching 60%) of the sensitivity of the beta-cell to glucose values 
within the normal fasting range. Disruption of post-load glucose control was characterized by a 
progressive decline (approaching 60%) of the slope of the full beta-cell vs glucose dose-response 
curve and an early minor (30%) decline of potentiation. The acute dynamic beta-cell responses, 
neither per se nor in relation to the degree of insulin resistance appeared to play a relevant role in 
disruption of fasting or post-load homeostasis. Follow-up data qualitatively and quantitatively 
confirmed the results of the cross-sectional analysis. 
Conclusion - In normal subjects fasting and post-load glucose homeostasis are largely independent, 
and their disruption is sustained by different and specific beta-cell defects. 





































































































































Maintenance of normal glucose homeostasis at the whole-body level requires the concerted 
action of multiple tissue and biologic systems and understanding which ones are responsible for the 
transition to pre-diabetes is crucial for the design of effective prevention strategies. One major 
challenge to this aim is that mild hyperglycemia per se, if persistent, might significantly affect two 
of the most important biologic systems: insulin secretion and insulin resistance [1] [2]. To gain 
insight on the primary mechanisms, therefore, the focus should be placed on the earliest stages of 
the transition, i.e. on normal subjects; a population that has seldom been extensively investigated in 
terms of all the key determinants of glucose homeostasis. A second challenge is that disruption of 
glucose homeostasis might involve either fasting or post-load plasma glucose control, each to an 
extent that is rather variable among individuals; a dissociation justified by the fact that the key 
processes responsible for the control of fasting and post-load glucose are different. Although the 
tissues involved are largely the same (liver, β and α-cells, skeletal muscle, adipose tissue, intestine), 
different can be the specific function/s that in each tissue is/are involved. In the last two decades, a 
series of studies have been conducted to understand the major defects that characterize the two 
conditions [3-8]. In synthesis, the loss of post-load glucose control, identified through 2hPG, was 
associated with variable degrees of whole-body and liver insulin resistance, and with marked 
impairments of both dynamic and static aspects glucose-stimulated insulin secretion. No alteration 
has been observed in glucose appearance [9]. Disruption of fasting glucose homeostasis, on the 
other hand, was found characterized by liver insulin resistance and a selective impairment in the 
acute/early insulin secretion, while other aspects of glucose-induced insulin secretion (2
nd
phase and
Potentiation) [10] were normal. Whole body insulin sensitivity, in this subgroup, has been found 
reduced [11], unaltered [12] and even increased [7]. 
Unfortunately, in addition to some qualitative inconsistencies among studies, there is also 


































































[7]. In particular, whether the defect in insulin secretion is absolute [8] or it emerges only in 
relationship to the degree of insulin resistance (failure of compensation) [10], and which is/are the 
earliest detectable defect/s remains unknown. While some of the variability depends on the ethnic 
background [13, 14] and the prevalence of obesity [15], the relatively small sample size (n=40-664) 
and the large heterogeneity (in number and quality) of the methods employed must have also 
contributed. Finally, another factor could be responsible for the lack of accurate and consistent 
information. All studies have used the canonical fasting and 2hPG cut-off plasma glucose values to 
categorize and compare the subjects; only few have used continuous values [3, 12, 16], and, most 
importantly, all somewhat neglected that fasting and 2hPG values are strongly correlated variables 
[17]. This implies that a substantial overlap exists between the two phenotypes when this strategy is 
adopted, and it should be carefully taken into consideration. Furthermore, from a physiology 
perspective, the control of post-load plasma glucose consists in limiting the rise above fasting 
levels, therefore it is better described by considering the whole plasma glucose excursion above 
basal values. However, to our knowledge, this approach has been used in only one study [18]. 
The aim of the present study is to accurately describe the whole spectrum of normal fasting 
and post-load glucose homeostasis, separately, by adopting a novel and more precise definition of 
post-load glucose tolerance, and to define the specific trajectories of the major metabolic 
derangements that characterize the transition to the pre-diabetic condition. To this end, we 
performed a secondary analysis on cross-sectional and longitudinal data from the Relationship 
between Insulin Sensitivity and Cardiovascular risk (RISC) study, a large cohort of individuals 
without diabetes extensively characterized in terms of glucose tolerance, insulin sensitivity and 
insulin secretion. 
2. Research design and methods
2.1 Study participants – The RISC study is a multicentre, prospective, observational, European 


































































participants were enrolled at 19 clinical centres in 14 European countries, according to the 
following inclusion criteria: either sex, age 30-60 years (balanced 10-year strata), and clinically 
healthy allowing for obesity up to class II (BMI<40 kg/m
2
). Exclusion criteria were: treatment for
any chronic disease, pregnancy, any cardiovascular disease or previous event, cancer, reduced 
kidney function (eGFR<60 ml/min/1.73m
2
) or known liver disease, hypertension, fasting plasma
glucose ≥7.0 mmol/l, 2-hour plasma glucose (on OGTT) ≥11.0 mmol/l, total cholesterol ≥7.8 
mmol/l, triglycerides ≥4.0 mmol/l. 
Of the initial cohort of 1,320 subjects who underwent the OGTT and the euglycemic insulin 
clamp, hepatic glucose production (tracer dilution) and acute insulin response during an IVGTT 
were measured in subgroups of 387 and 843 subjects, respectively. Thirty-one subjects were 
excluded for problems in the baseline biochemical parameter determination (missing values, 
outliers, poor quality control, internal inconsistencies) therefore the present analysis is based on the 
baseline data of 1,289 subjects. Local Ethics Committee approval was obtained by each recruiting 
center and subjects signed an informed consent. 
2.3 Euglycemic insulin clamp - Insulin was administered as a primed-continuous infusion at a 




; simultaneously plasma glucose levels were maintained within 4.5-5.5







) was calculated as the ratio of the glucose infusion rate (M value), averaged over the
final 40 min of the 2-hours clamp and normalized by the fat-free mass (FFM), measured by 
bioimpedance (TB300, TANITA, Tokyo, Japan), and to the achieved plasma insulin concentration. 
Then, we then adjusted the M/I value by the clamped glucose level obtaining the ratio of glucose 
clearance during clamp (GCRc/Ic), obtaining a more precise index of peripheral insulin sensitivity. 
At the end of the clamp in the IVGTT subgroup (n=847) a bolus of glucose (0.3 mg/kg of body 
weight) was injected intravenously over 1 min and blood samples collected every 2 min for 8 min. 
In another subgroup (n=387) endogenous glucose production (EGP) was measured with [6-6
2
H2]


































































calculated as the ratio of EGP to fasting glucose levels. The ratio of GCRf to fasting insulin levels 
(GCRf/If), was adopted as measure of whole-body fasting insulin sensitivity. 
2.4 Analytical methods - Plasma and serum aliquots were stored at -80ºC for centralized 
analytes determination. Serum total cholesterol, HDL-C, LDL-C and triglycerides were measured 
by enzymatic colorimetric test (Roche Modular systems), NEFA by an immunoenzymatic assay 
(Randox), plasma insulin and C-peptide by a time resolved fluorimmunoassay (AutoDELFIA 
Insulin kit, Turku, Finland). The glucagon assay used an in-house assay developed in J. Holst’s 
laboratory in Copenhagen. 
2.5 Beta cell function - Parameters of beta-cell function were generated by using the OGTT C-
peptide and glucose data. The characteristics of the model used to reconstruct insulin secretion and 
its control by glucose has previously been described in detail [20]. In brief, the analysis consists of 
three interacting blocks: a) a model for smoothing and interpolating plasma glucose profile based on 
the available determinations; b) a model of C-peptide kinetics individually adjusted to the subject's 
anthropometric data according to Van Cauter et al. [21]; c) a model for describing the dependence 
of insulin secretion on glucose concentration. With regard to the relationship between insulin 
release and plasma glucose concentrations (block c), it is modeled as the sum of two components. 
The first component represents the dependence of insulin secretion on the absolute glucose 
concentration at any time point and is characterized by a quasi-linear dose-response function whose 
slope is defined as beta-cell glucose sensitivity (βC-GS). This parameter can be modulated by 
several factors (i.e., non-glucose substrates, gastrointestinal hormones and neurotransmitters), 
which are collectively modelled as a potentiation factor whose value is set to be a positive function 
of time, and to average the value 1 during the duration of the 2-h OGTT. The ratio of the values at 
100-120 min vs 0-20 min (potentiation factor ratio, PFR) is used to express with a single parameter
this component. The second insulin secretion component represents a dynamic dependence of 
insulin secretion on the rate of change of glucose concentration and is denoted as rate sensitivity 


































































that in each individual would occur at 5 mM glucose reflecting the basal (non-stimulated) beta-cell 




) is the value of insulin
secretion measured at time 0 while the total OGTT insulin secretion (ISR OGTT, nmol·m
-2
) is the
integral of insulin secretion during the entire 2-hour OGTT. Peripheral insulin clearance was 
calculated as the ratio of insulin infusion rate to steady state plasma insulin during the clamp. The 
acute insulin response (AIR/G) during the IVGTT was calculated as the ratio of the area under the 
curve of C-peptide to the maximal plasma glucose concentration gradient achieved with the bolus 
over 8 minutes. No significant inhibition of endogenous insulin release during clamp was detected. 
2.6 Follow-up - 1,038 subjects underwent a second visit and OGTT after 3.5 years according to 
the same protocol adopted at baseline; neither the clamp nor the IVGTT in this occasion was 
performed (249 subjects were lost at follow-up, 2 subjects were excluded for fasting plasma glucose 
values ≥7 mM). Changes are always calculated as 3.5 years – baseline. FPG and δOGTT 
progressors were defined as individuals within the fourth quartile of the distribution of the 
individual changes over the follow-up in either parameter. Subject with a spontaneous decline in 
either ISR@5 or in βC-GS were defined as those in the lowest tertile of the distribution of the 
absolute changes in either parameter over 3.5 years. 
2.7 Statistical analysis - Statistical analysis was performed using JMP®Pro11.2 software (SAS 
Institute Inc., Cary, NC). Data are reported as mean ± standard deviation or median [interquartile 
range], unless otherwise specified. 
All continuous variables were tested for normality via Kolmogorov-Smirnoff-Tests and 
normalized via logarithmic transformation before analysis when appropriate. Differences between 
means and rates have been evaluated with ANOVA and chi-squared tests, respectively. The subjects 
were classified according to quintiles of FPG and quintiles of mean plasma glucose increment 
(above fasting) during the OGTT (δOGTT). Statistics on major variables was tested through two-
way ANCOVA always including both classification criteria and major confounders (age, sex, BMI 


































































interaction was also tested. Correlations between variables were tested using Pearson's or 
Spearman’s rank correlations as appropriate. To allow a direct comparison, the estimated 
multivariable regression coefficients were expressed as standardized coefficients (Stβ). 
3. Results
In the whole population, both FPG and δOGTT displayed a quasi-normal distribution and were 
very weakly correlated (r=0.12, p<0.0001) (Figure 1a). The poor association was confirmed by a 
minimal, although statistically significant, increment of δOGTT through FPG quintiles (Figure 1b). 
Similarly, statistically significant, but small was the progressive rise in FPG across quintiles of 
δOGTT with a maximum gradient of 0.19±0.14 mM between the two extremes (p<0.0001) (Figure 
1b). Of note, the association between FPG and 2hPG was stronger (r=0.28, p<0.0001) (Figure 1a) 
and 2hPG values showed a progressive and significant rise through FPG quintiles reaching a 
maximum gradient between extreme quintiles of 1.07±0.12 mM (Figure 1b). The association of 
FPG with 2hPG was stronger than that with δOGTT also after adjusting for sex, BMI, age and 
center (Stβ=0.29 vs 0.12). 
3.1 Clinical phenotypes 
Plasma glucose and insulin profiles during the OGTT across quintiles of FPG and δOGTT are 
presented in Figure 2. Both phenotypes (Table 1), of worse fasting and post-load glucose control, 
showed a superimposable profile in terms of age and BMI, with a similar quasi-linear increase 
across quintiles. A progressive enrichment in male sex was present as FPG increased, while this 
was only marginally evident across δOGTT quintiles. For these reasons, differences for the other 
parameters across quintiles of FPG and of δOGTT, were tested with a two-way ANCOVA that 
included age, sex, BMI and center, in addition to the two classification criteria. Disruption of both 
fasting and post-load glucose homeostasis was associated with a rising prevalence of family history 


































































subjects with Impaired Fasting Glucose (IFG) were all in the 5
th
 quintile of FPG representing
approximately 60% of the subjects of this subgroup, while individuals with IFG were present in all 
quintiles of δOGTT with prevalence rates ranging from 7 to 22%. Similarly, subjects with Impaired 




 quintiles of δOGTT (8 and
64%), while they were present in all quintiles of FPG at rates ranging from 6 to 15%. 
With regard to the other major metabolic syndrome parameters, we observed that while the 
individuals with worse post-load glucose homeostasis were characterized by higher triglycerides 
and lower HDL cholesterol, those with higher FPG had higher blood pressure values and ALT 
levels. 
Plasma glucagon was not affected by the degree of disruption of either fasting or post-load 
glucose homeostasis, while a progressive rise in plasma NEFA was found through the δOGTT 
quintiles only. 
3.2 Beta-cell function, insulin clearance and insulin sensitivity parameters 
Parameters of beta-cell function were associated with specific trends while approaching pre-
diabetes in each phenotype (Table 2, Figure 3). Subjects with progressively loss of fasting glucose 
homeostasis displayed decreasing values of ISR@5, which was coupled to a mild (20% max.) 
increase of PFR and a mild (15% max.) decrease in AIR/G. In contrast, the deterioration of post-
load glucose control was characterized by an early and stable reduction (30%) in PFR, a gradual 
major reduction of βC-GS (60% max.) and a transient increase in RS. A mild (15%) AIR/G 
reduction was observed also across δOGTT quintiles. Peripheral insulin clearance was similar 
across quintiles of both FPG and δOGTT. Insulin sensitivity in the stimulated condition, measured 
through GCRc/Ic, showed a progressive reduction only across δOGTT quintiles, with a 35% 




 quintile. When GCRc/Ic was plotted against AIR/G and data fitted
with 1/x functions (to assess compensation), no significant difference among the curves (neither in 


































































subjects in the 5
th
 quintile of δOGTT showed a 50% reduction in the 1/(GCRc/Ic) coefficient
indicating a significant defect in compensation, which was evident in the subset of individuals with 
severe insulin resistance (Figure 4). 
In the subgroup of subjects in whom glucose tracer data were available (n= 387) (Table 2), 
fasting endogenous glucose production (EGP) was remarkably stable across quintiles of both fasting 
or post-load glucose homeostasis. As expected, glucose clearance in the fasting condition 
progressively declined only across quintiles of FPG, and whole-body fasting insulin sensitivity 
(GCRf/If) showed an even more marked decline. EGP measured in conditions of high-normal 
plasma insulin levels (at steady state during the clamp) was similarly suppressed in all study groups 
(data not shown). 
In multivariable regression analysis, ISR@5 was the major determinant of FPG (Stβ=-0.42) 
with minor contributions of male sex (Stβ=0.15, p<0.0001), BMI (Stβ=-0.15, p<0.0001) and age 
(Stβ=0.09, p<0.0001) together contributing to 48% of its overall variability.  βC-GS, GCRc/Ic, and 
RS were the major determinants of δOGTT (Stβ=-0.44, -0.23, -0.18, respectively p<0.0001) 
explaining 45% of its overall variability. 
3.3 Follow-up 
Six subjects had 2hPG values ≥11.0 mM at OGTT (mean±SD=12.2±1.1 mM) and were left in 
the analysis. In the population undergoing the 3.5-year follow-up (n=1,038), the changes in FPG 
and δOGTT were largely independent showing, if anything, an inverse correlation (r=-0.08, 
p=0.01). Only 25% of the FPG and δOGTT progressors fell in the 4
th
 quartile of the change for both
parameters.  FPG increased by 0.8 and 0.1 mM in FPG and δOGTT progressors, respectively; while 
δOGTT doubled in δOGTT progressors and did not change in FPG progressors (Table 3, Figure 5). 
BMI showed a modest increase in both phenotypes (+0.6 units). Fasting insulin secretion (ISR fast) 
increased by 15% only in FPG progressors and the increase in total OGTT insulin secretion (ISR 


































































whom fasting and post-load glucose control deteriorated exhibited changes in the major glucose 
homeostatic parameters (Table 3) that closely followed the curves built on the bases of the analysis 
on cross-sectional data (Figure 3). In the whole dataset changes in ISR@5 and βC-GS were 
unrelated (r=0.03, p=ns). Changes in ISR@5, though weakly, were negatively correlated with 
changes in PFR (r=-0.13, p<0.001), while the changes in βC-GS showed a positive correlation (i.e. 
concomitant disruption) with changes in PFR (r=0.22, p<0.001) and a negative correlation with the 
changes in RS (r=0.19, p<0.0001). 
In order to appreciate the impact on glucose tolerance of a selective decline in ISR@5 or in βC-
GS and of concomitant decline of both beta-cell functions, we plotted the baseline and 3.5 years 
OGTT curves of the subjects who fell in the 1
st
 tertile of the spontaneous changes for each
parameter either isolated (n=209 and n=209, respectively) or in combination (n=116) (Figure 6). A 




) resulted in an increase of 0.4±0.5
mM in FPG (p<0.0001) with no change in δOGTT (0.0±1.1 mM), while a 40% decline in βC-GS 







  resulted in an increase of 0.6±1.1mM in δOGTT
(p<0.0001) and no change of FPG (0.1±0.5mM). In the subgroup in whom both ISR@5 and βC-GS 
declined at follow-up (by 50% and 46%, respectively) we observed a worsening of both FPG 
(0.5±0.7 mM) and δOGTT (0.5±1.1 mM). ISR fast was, if any, reduced in the ISR@5 and 
ISR@5+βC-GS progressors groups and showed a modest (10%) increase in βC-GS individuals. 
Total insulin secretion (ISR OGTT) did not differ among study groups. 
4. Discussion
4.1 Pathophysiological findings 
Our findings indicate that in subjects without diabetes fasting and post-load glucose 


































































stratified according to quintiles of increasingly worse fasting or post-load glucose control, only a 
minority (23%) fell in the same quintile (i.e. had the same degree of alteration for both criteria), 
indicating that the derangements in the two systems occur in parallel only in a minority of 
individuals. This dissociation, coupled to our multivariable adjustment, allowed us to detect and 
quantify across the whole spectrum of non-diabetes glucose homeostasis, the major clinical and 
physiologic characteristics that characterize each condition, an information not available in the 
literature. 
In terms of clinical phenotype the closer association of dyslipidemia with post-load glucose is 
congruent with the known inhibitory effect of triglycerides and HDL-cholesterol on glucose 
stimulated beta cell function [22, 23], while the association of fasting glucose with waist is likely to 
be driven by the effect of visceral fat on liver insulin sensitivity [24]. 
In terms of mechanisms, our data indicate that disruption of fasting glucose control is 
essentially characterized by the inability of the beta-cell to efficiently increase insulin secretion for 
glucose concentration values that lie within the fasting normal range. In these subjects, higher 
plasma glucose levels are required by the beta-cell to secrete the amount of insulin that is necessary 
to match endogenous glucose production (which appears to be a true homeostatic variable) to whole 
body glucose utilization. Interestingly, when fasting insulin secretion is plotted vs FPG according to 
quintiles of FPG (Figure 7a), the linear fit of this dose-response curve displays a slope of 21, while 
the slope across quintiles of δOGTT is 98 i.e. close to the slope of the full beta-cell dose-response 






, IQR [78-158]). In other
words, the same 35% increase in fasting insulin secretion (presumably required to overcome hepatic 
insulin resistance) is observed across quintiles of both δOGTT and FPG, however for the latter an 8-
fold larger FPG gradient is needed (1.6 vs 0.2 mM). This clearly demonstrate a severe beta-cell 
insensitivity that is restricted to the normal fasting glucose values, the beta-cell response to post-


































































severe fasting insulin resistance (GCRf/If) viz an essentially preserved stimulated insulin sensitivity 
(GCRc/Ic). The higher FPG is probably responsible for the relative increase in potentiation [5], 
which in turn may contribute to the maintenance of post-load glucose homeostasis and justify the 
dissociation of the two phenotypes. With regard to the mechanisms underlying this distinct beta-cell 
insensitivity, i.e. restricted to the fasting condition, we could not find any clear, strong and plausible 
signal among candidate variables, including energy substrates, hormones and clinical parameters. 
The persistence of stable plasma glucagon values viz elevated glucose levels might suggest a 
reduced α-cell sensitivity to glucose in these subjects. 
A 50% decline in ISR@5 has been observed also by Kanat et al [10] in a small study in 
Mexican Americans with IFG when compared to NGT/NFG, however no information was given on 
the trajectory of the defect in relation with FPG.  In contrast with other laboratories, we observed 
only a modest decline in acute/early insulin secretion in subjects with mild elevation in FPG. 
However, in the study of Bogardus et al [3] the cross-sectional FPG vs AIR curve was U-shaped 
and a true decrease was evident only for fasting glucose values above 6.0 mM; also in a study by De 
Fronzo et al [10] the association between AIR and FPG was essentially driven by the low AIR of 
the subjects with FPG above 6.0 mM. The defect, in addition is known to depend on the ethnic 
background being severe in Hispanic, mild in African American and negligible in White [14]. 
Finally, our IVGTT test was performed with plasma glucose clamped at approx. 5.0 mM in all 
subjects. Provided that hyperglycemia, also of mild degree (+2.8 mM), is able to blunt the 1
st
 Phase
insulin secretion [25], the severe reduction in AIR observed by other laboratories - with tests 
performed at the fasting glucose values - could be a secondary phenomenon. A similar increase in 
potentiation in subjects with isolated IFG has been observed also by Kanat et al in a small cohort of 
Mexican Americans [10], however they also found a major reduction in RS and βC-GS in these 
subjects. This apparent discrepancy may have arisen because subjects with IFG were compared with 


































































in whom βC-GS is particularly high; in fact, the NGT group had a βC-GS similar to our 2
nd
 δOGTT
quintile.   
The deterioration of post-load glucose homeostasis is characterized by the combination of a 
severe reduction in βC-GS (Figure 3 and 5) coupled to a marked reduction of both potentiation and 
stimulated whole-body insulin sensitivity. The decline in the AIR/G, mild in size, when evaluated 
with respect to the prevailing insulin sensitivity, demonstrated that the defect in compensation was 
only present in the subjects of the extreme quintile and with extreme insulin resistance (Figure 4). 
RS, another proxy of acute insulin response, showed an early, transient and modest increase 
followed by a decline across quintiles of δOGTT confirming that the lack of beta-cell adaptation to 
the degree of insulin resistance becomes evident only while approaching the diabetic condition. A 
U-shaped relationship between acute insulin response and post-load glucose was also found by
Bogardus et al. [3]. In the prospective data both worsening of post-load glucose homeostasis 
(Figure 3), and also of βC-GS (r=-0.19) were associated with an improvement in RS. We conclude 
that defective compensation has a minor role being evident only in those with more severely 
impaired post-load glucose regulation (5
th
 quintile of δGOTT) and with severe insulin resistance
(Figure 4). 
Another novel, and rather unexpected, finding is the early decline of potentiation reaching a 
35% reduction already for an intermediated degree of derangement (3
rd
 δOGTT quintile) with no
further decline while approaching the pre-diabetes condition. The observed preservation of insulin 
secretion at low-fasting glucose levels (ISR@5) probably prevents the concomitant loss of fasting 
plasma glucose control and justifies the dissociation of the two conditions. In quantitative terms, 
multivariable analysis indicated that βC-GS, insulin sensitivity and RS, in this order, appears to be 
the major factors characterizing the deterioration of post-load glucose homeostasis. The decline of 
distinct beta-cell functions therefore appears to be a continuous phenomenon already evident in the 


































































diabetes. This is in deep contrast with the consolidated notion that in the stages preceding the onset 
of type 2 diabetes there is a compensatory beta-cell hyperfunction as the evident hyperinsulinemia 
might suggest. The only small somewhat compensatory beta-cell responses are PFR and RS for 
fasting and post load glucose homeostasis, respectively. 
4.2 Clinical relevance 
In terms of clinical relevance, the different metabolic profiles of deterioration in post-load and 
fasting glucose homeostasis could help in stratifying treatments and in generating more accurate 
hypotheses to be tested in prospective prevention trials. The availability of heterogeneous classes of 
pharmacologic glucose lowering agents makes it possible to envisage tailored strategies targeting 
selectively the major specific defects of each condition. Thus, metformin by acting, already at low 
doses, on liver insulin sensitivity and fasting glucose clearance [26] may be more effective in 
targeting fasting hyperglycemia, while exercise, diet and weight loss (or thiazolidinediones), being 
more effective in restoring systemic insulin sensitivity [27], and incretins, acting mainly on oral 
glucose stimulated insulin secretion, would be rational choices for preserving post-load glucose 
homeostasis. 
4.3 Strengths and limitations 
Strengths of this study are: the dimension of the population, the extensive metabolic 
characterization, the availability of follow-up data, the more physiologic definition of fasting and 
post-load glucose homeostasis and the robust multivariate approach adopted to detect the specific 
defects of each condition (adjustments for confounders and cross adjustment of FPG and δOGTT).  
A limitation of this study is its large reliance on cross-sectional data, however the follow-up 
data, though limited in time, are in full agreement with the cross-sectional analysis, strengthening 


































































homeostasis was, if anything, even more evident in the follow-up analysis and the changes in the 
various beta-cell functions were qualitatively and quantitatively superimposable to the ones 
predicted from cross-sectional trajectories (Figure 3). On the other hand, and most importantly, also 
the impact of the spontaneously occurring declines in ISR@5 and in βC-GS resulted in deterioration 
of fasting and post-load glucose homeostasis (Figure 6), respectively, which were in qualitative and 
quantitative terms very close to what predicted from the cross-sectional analysis. Another limitation 
is that δOGTT does not represent a clinical meaningful variable in itself, in this respect both 1h and 
2h OGTT glucose values are undoubtedly more relevant since they are established predictors of 
diabetes, however an elegant study by Abdul Ghani et al [28] has clearly shown that among normal 
and IGT subjects with identical fasting and 2h glucose the risk to develop diabetes is proportional to 
the incremental area under the plasma glucose curve (i.e. δOGTT·120). The characteristics of our 
study population, with a large fraction of subjects with normal glucose tolerance, might have led to 
an overestimation of the defects underlying impaired glucose homeostasis, however as evident also 
from our results the deterioration of glucose homeostasis is a continuous phenomenon with no clear 
threshold and the description of the trajectories contains information with regard to the dynamics 
and the relevance of the defects at the bases this phenomenon. We also acknowledge that the 
IVGTT data, used to determine first-phase insulin secretion, might be influenced by the antecedent 
exogenous insulin administration, which is known to inhibit unstimulated endogenous insulin 
secretion especially in subject with insulin resistance [29-32]. Indeed, we observed a correlation 
between insulin resistance and the decline in plasma C-peptide during the clamp (r=0.24, 




































































In normal subjects the deterioration of fasting and post-load glucose homeostasis are largely 
independent phenomena and are characterized by the decline of distinct beta-cell functions, which 
are progressive and appear already at the earliest stages of metabolic derangement in absence of 
relevant compensatory responses. These novel notions could be exploited for a direct clinical 



































































Figure 1 – (a) Scatterplot and frequency distribution of fasting plasma glucose (FPG) vs mean 
plasma glucose above fasting levels (δOGTT) and 2h plasma glucose (2hPG) in the 1,289 subjects 
at baseline. R
2
 values represent the strength of the correlation between FPG and δOGTT and FPG
and 2hPG; (b) Histogram bars of mean and SE values of FPG (black), δOGTT (dark grey) and 
2hPG (light grey) according to quintiles of FPG and δOGTT. 
Figure 2 – OGTT plasma glucose (upper panels) and insulin (lower panels) mean and SEM values 




, from the left to the right) of fasting (FPG) (left panels) and post-load
plasma glucose (δOGTT) (right panels) in the 1,289 subjects at baseline. 
Figure 3 - Plot of insulin secretion, endogenous glucose production (EGP) and insulin sensitivity 
parameters expressed as percent of first quintile of fasting (FPG) and post-load plasma glucose 
(δOGTT) across quintiles of FPG and δOGTT. Values are adjusted for age, BMI, sex, recruitment 
centre and also the cognate classification criteria in the 1,289 subjects at baseline. Arrows indicate 
the changes of the beta cell function parameters that showed a significant variation at the 3.5 years 
follow-up in the 25% of subjects (of the 1,038 at follow-up; data are available only for insulin 
secretion) who displayed the largest spontaneous increase in either FPG or δOGTT. Continuous 
lines indicate that the means were found statistically different, dotted lines were not. 
βC-GS: beta-cell glucose sensitivity; AIR/G: ratio of the area under the curve of C-peptide to the 
maximal plasma glucose concentration gradient achieved with the bolus over 8 minutes; GCRf/Ic: 
ratio of glucose clearance at fasting and insulin;: ratio of glucose clearance during clamp; ISR@5: 
Insulin Secretion Rate at glucose 5 mM; ISR fast: Insulin Secretion Rate at fasting glucose 
concentrations; ISR OGTT: Insulin Secretion Rate at OGTT glucose concentrations; PFR: 
Potentiation Factor Ratio; RS: Rate sensitivity. 
Figure 4 – Best (y=a+b*1/x) fit of AIR/G (on y axis) and glucose clearance during clamp (GCRs/Ic) 
in each fasting plasma glucose (FPG) quintile (upper panel) and each post load glucose control 
(δOGTT) quintile (lower panel). Only the b coefficient for the 5
th
 δOGTT quintile was statistically
significant different from the others (Dunnet tests). 
Figure 5 – OGTT plasma glucose at baseline and after 3.5 years of follow-up values in the subjects 
who displayed the greater deterioration (>75% percentile of the 1,038 subjects at follow-up) of 



































































Figure 6 – OGTT plasma profiles at baseline (gray) and at 3.5 follow-up (black) in the individuals 
in whom a spontaneous and selective decline (>67% percentile) of ISR@5 (ISR@5↓ βC-GS→; 
n=209), or βC-GS (ISR@5→ βC-GS↓; n=209) or both (ISR@5↓ βC-GS↓; n=116) has occurred. 
βC-GS: beta-cell glucose sensitivity; ISR@5: Insulin Secretion Rate at glucose 5 mM. 
Figure 7 – a) Scatterplot of fasting plasma glucose vs fasting insulin secretion in quintiles of fasting 
plasma glucose (FPG) (gray) and post load glucose control (δOGTT) (black) with regression dose-
response lines calculated on mean values. b) Insulin secretion and plasma glucose dose-response 
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Table 1 - Clinical characteristics of the study population stratified according to quintiles of fasting plasma 
glucose (FPG) and OGTT mean plasma glucose (δOGTT). The EGIR-RISC study 
Quintile Groups 
I II III IV V p-values*
n FPG 265 256 211 273 286 
δOGTT 259 258 260 259 255 
Age 
(years) 
FPG 41±8 43±8 43±9 45±8 46±8 <0.0001 
δOGTT 42±8 43±9 45±9 45±8 46±8 <0.0001 
 Male 
(%) 
FPG 25 35 46 51 64 <0.0001 





FPG 24.2±4.2 24.7±4.0 25.1±3.6 25.9±3.7 27.1±3.9 <0.0001 





FPG 30[11-63] 41[11-85] 25[23-28] 50[15-114] 66[15-135] ns 
δOGTT 42 [15-105] 39 [11-90] 46 [15-91] 48 [15-106] 51 [15-131] ns 
Smokers 
(nev./ex/curr.) 
FPG 49/31/20 47/24/29 44/30/26 46/25/29 45/25/30 ns 
δOGTT 48/25/27 46/23/31 47/25/28 46/25/29 45/35/20 ns 
FHD 
(%) 
FPG 22 26 22 30 36 0.0024 
δOGTT 19 22 25 30 39 0.0057 
IFG 
(%) 
FPG 0 0 0 0 58.7 ns 
δOGTT 7 8 13 14 22 <0.0001 
IGT 
(%) 
FPG 5.7 5.5 9.5 9.5 15.0 ns 
δOGTT 0 0 0 8 64 <0.0001 
SBP 
(mmHg) 
FPG 113±12 115±12 118±12 118±12 123±12 0.0050 
δOGTT 115±12 117±12 118±12 118±14 120±11 ns 
DBP 
(mmHg) 
FPG 72±8 73±8 75±8 75±8 77±7 0.0169 





FPG 4.6±0.9 4.7±0.9 4.8±0.8 4.9±0.9 5.1±0.8 ns 





FPG 2.7±0.8 2.8±0.8 2.9±0.8 3.0±0.8 3.1±0.8 ns 





FPG 1.5±0.4 1.5±0.4 1.4±0.4 1.4±0.4 1.3±0.4 ns 





FPG 0.9±0.5 1.0±0.5 1.1±0.7 1.2±0.7 1.4±1.0 ns 





FPG 17±10 18±10 19±9 21±10 24±15 0.0199 





FPG 21±8 21±9 21±9 22±8 23±11 ns 





FPG 8.5±4.1 8.8±3.5 9.3±4.7 9.1±4.2 9.4±4.1 ns 





FPG 575±283 541±225 535±228 539±209 512±206 ns 
δOGTT 497±196 549±254 527±216 556±241 582±286 <0.0001 




ANOVA for age, BMI, sex with FPG and δOGTT as independent variables, both in the model; for the other
variables; two-way
 
ANCOVA with independent variables FPG, δOGTT, and covariates age, BMI, sex and recruitment center; 


































































Table 2 - Insulin secretion and insulin sensitivity indices of the study population stratified 
according to quintiles of fasting plasma glucose (FPG) and OGTT mean plasma glucose 
(δOGTT).  The EGIR-RISC study 
Quintile Groups p-
values* 







FPG 65.2±26.4 65.3±26.9 75.2±35.0 78.8±33.1 94.2±38.6 <0.0001 





FPG 38.7±12.7 39.2±13.2 40.4±15.4 43.0±14.4 44.2±14.2 0.0297 







FPG 131±81 81±36 72±35 61±32 55±36 <0.0001 









FPG 147.9±106.4 143.1±88.2 133.8±95 128.3±83.2 110.6±64.7 ns 







FPG 801 [0-1478] 782 [122-1441] 862 [121-1349] 885 [274-1572] 637 [230-1196] ns 
δOGTT 833 [0-2382] 848 [0-1678] 844 [245-1390] 807 [351-1228] 691 [287-1061] <0.0001 
PFR FPG 1.5 [1.1-2.3] 1.7 [1.2-2.5] 1.6 [1.1-2.5] 1.7 [1.2-2.4] 1.8 [1.4-2.4] 0.0015 





FPG 68±36 67±38 63±34 58±35 58±30 0.0009 







FPG 0.64±0.35 0.62±0.15 0.62±0.15 0.61±0.17 0.63±0.26 ns 









FPG 0.031±0.019 0.030±0.014 0.030±0.015 0.027±0.014 0.025±0.014 ns 







FPG 15.9±3.5 17.5±6.0 15.8±5.2 16.1±4.6 16.1±4.5 ns 









FPG 0.14±0.07 0.14±0.10 0.12±0.10 0.10±0.10 0.08±0.05 0.0002 
δOGTT 0.14±0.11 0.12±0.07 0.11±0.06 0.11±0.06 0.09±0.06 ns 
Data shown are n, %, mean±SD 
° AIR-∂Cp/∂G number of subjects n= 848 
°° EGP number of subjects n= 387 
* 
p-values  from two-way ANCOVA on FPG and δOGTT, adjusted for covariates age, BMI, sex and recruitment center; interactions


































































Table 3 – Baseline and 3-year follow-up data of progressors (4
th
 quartile of 
change in FPG or δOGTT). The EGIR-RISC study 
Data shown are mean±SD, or median [interquartile range] 
*p-values from unadjusted paired t-tests





FPG 4.8±0.5 5.6±0.6 <0.0001 





FPG 2.2±1.3 2.2±1.5 ns 





FPG 25.7±3.9 26.3±4.4 <0.0001 







FPG 75±30 87±35 <0.0001 





FPG 42±14 45±16 <0.0001 







FPG 95±64 57±37 <0.0001 
δOGTT 85±75 77±98 ns 
PFR FPG 1.6 [1.1-2.3] 1.7 [1.2-2.5] ns 







FPG 851 [201-1404] 706 [276-1287] ns 









FPG 123±84 113±69 ns 
δOGTT 150±109 111±58 <0.0001 







